article thumbnail

The potential of virtual reality-based therapy for serious mental disorders

Pharmaceutical Technology

In 2020, OxfordVR secured a $12.5m XRHealth launched a VR therapy application in 2020 designed to treat attention deficit hyperactivity disorder (ADHD). Treatment delivered this way is cost-effective and less time-consuming for both physicians and patients compared with pharmacological interventions.

article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

There is a clear trend away from developing pharmacological therapies targeting opioid receptors” There is a clear trend away from developing pharmacological therapies targeting opioid receptors. Neuropathic pain in adults: pharmacological management in non-specialist settings – NCBI Bookshelf. Pain and Therapy.

Medicine 102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Click Therapeutics kicks off digital therapy remote trial for migraine

Pharmaceutical Technology

Digital therapy is becoming prevalent as a viable treatment path for companies seeking to increase treatment accessibility by reducing barriers that accompany pharmacological interventions. Click teamed up with Boehringer Ingelheim in September 2020 to develop and commercialise a digital therapeutic to treat schizophrenia.

article thumbnail

Understanding a rare disease through the lens of real world and prevalence data

Clarivate

4; 4/20/2020; DOI:10.7759/cureus.7745 ” Molecular Vision; 12/28/2020; p789 [5] Sahel J et al. 5; 5/2020; p679; DOI: 10.1016/j.ophtha.2019.11.014 Frontiers in Pharmacology; 13:1089033; DOI: 10.3389/fphar.2022.1089033 . “Leber Hereditary Optic Neuropathy: Case Report and Literature Review.”

article thumbnail

Patents: a necessary evil?

European Pharmaceutical Review

The Evergreening Myth, Fall 2020. 2020-02-24. Patent Protection of Pharmacologically Active Metabolites: Theoretical and Technological Analysis on the Jurisprudence of Four Regions. Working Paper 20548, National Bureau of Economic research (NBER). Internet] [link]. Cited 25 September 2022]. Letter to FDA, 06 July 2022.

article thumbnail

Neuraxpharm partners with mjn-neuro on epilepsy wearable

pharmaphorum

The platform has been developed with support from the EU’s European Institute of Technology Health (EIT Health) and funding from the Horizon 2020 programme, along with industrial and academic partners.

article thumbnail

FDA suggests ways to curb constraints with rare disease gene therapy trials

Pharmaceutical Technology

In 2020, the FDA released a guidance document for the industry with recommendations for sponsors developing gene therapies for rare diseases. This document delved into aspects related to manufacturing, preclinical, and clinical trial design for all phases of clinical development.

FDA 105